Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2026)

Amneal Pharmaceuticals has reported Accumulated Expenses for 8 years, with the latest figure at $18.5 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses fell 55.47% year-over-year to $18.5 million in Q2 2026; TTM through Jun 2026 was $18.5 million, a 55.47% decrease from a year earlier, with the FY2025 full-year figure at $43.3 million, up 36.22% from the prior year.
• Accumulated Expenses was $18.5 million for Q2 2026 at Amneal Pharmaceuticals, up from $10.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $275.3 million in Q2 2022, with the low at $10.5 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $69.8 million, with a median of $43.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses soared 85.32% in 2022, then slumped 75.75% in 2026.
• Over 5 years, Accumulated Expenses stood at $107.5 million in 2022, then declined by 28.37% to $77.0 million in 2023, then sank by 58.75% to $31.8 million in 2024, then surged by 36.22% to $43.3 million in 2025, then slumped by 57.26% to $18.5 million in 2026.
• The last three Accumulated Expenses figures came in at $18.5 million (Q2 2026), $10.5 million (Q1 2026), and $43.3 million (Q4 2025), per Business Quant data.